Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ri

Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park

The Ritedose Corporation, a leading pharmaceutical manufacturer specializing in Blow-Fill-Seal (BFS) technology, today unveiled its new distribution a

Ritedose Corporation
Ritedose Corporation
3 min read

The Ritedose Corporation, a leading pharmaceutical manufacturer specializing in Blow-Fill-Seal (BFS) technology, today unveiled its new distribution and logistics facility at Performance Park during a ribbon-cutting ceremony. The grand opening event included Ritedose CEO Jody Chastain, state and county officials, community leaders, and key partners in the life sciences ecosystem. 


At the heart of Performance Park is a new 225,000-square-foot central distribution and logistics center that expands Ritedose’s capabilities to handle well over 2 billion doses per year. The new facility is part of a multiphase $81M investment that has created an additional 100 new jobs. This major investment reflects Ritedose’s ongoing commitment to innovation, workforce development, and the future of both South Carolina’s $25.7 billion life sciences industry and the country’s.  

 

This year marks Ritedose’s 30th year, and the company has been making significant advancements both operationally and for the community:  


A 2024 expansion of high-speed Blow-Fill-Seal lines that added 180-million-unit dose capacity for ophthalmic and respiratory medications 

 

The addition of a seventh Syntegon packaging line that doubled capacity to package individually wrapped vial medications 

 

Becoming the manufacturing partner of choice for Verona Pharma’s new COPD drug Ohtuvayre 

 

Securing several FDA approvals for new COPD and asthma medications—helping address a national shortage of Albuterol 

 

read more


More from Ritedose Corporation

View all →

Similar Reads

Browse topics →

More in Business

Browse all in Business →

Discussion (0 comments)

0 comments

No comments yet. Be the first!